Brian Rekoske

Brian Rekoske joined the McNeel lab in December 2012 as a graduate student in the Microbiology Doctoral Training Program.

As the field of tumor immunology expands, more attention has been given to the immune regulatory processes that affect the efficacy of tumor immunotherapies. CTLA-4 and PD-1 have been identified as two T-cell inhibitory receptors that play an important role in modulating cancer immunotherapy. Clinical trials have been launched to explore the anti-tumor efficacy of CTLA-4 and PD-1 blockade alone, as well as the efficacy of co-administering these with established immunotherapeutic agents.

Brian's work is aimed at understanding the immune regulatory processes occurring in the prostate cancer tumor microenvironment and designing optimized cancer immunotherapies that can avoid these levels of regulation.